They encompass plenty of concerns in the field of COVID-19-related Otorhinolaryngology research, comprising “#0 quality of life,” “#1 hearing loss,” “#2 olfactory dysfunction,” “#3 dupilumab,” “#4 ace2 receptor,” “#5 coronavirus disease 2019,” “#6 allergic rhinitis,” “#7 angiotensin-converting enzyme 2,” “#8 smell loss,” “#9 encephalitis.” COVID-19-related quality of life, pathophysiological mechanisms, and Otorhinolaryngology-related symptoms are still hotspots in the study of COVID-19 ENT-related symptoms. This evidence concerns the gene ACE2 and COVID-19.